HIMALAYA: learning from another negative phase 2 trial in ALS

Orla Hardiman

Open source

DOI
10.1016/s1474-4422(26)00318-2
Published
2026-10
Container
The Lancet Neurology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-26-00318-2,
  title = {HIMALAYA: learning from another negative phase 2 trial in ALS},
  author = {Orla Hardiman},
  year = {2026},
  journal = {The Lancet Neurology},
  doi = {10.1016/s1474-4422(26)00318-2},
  url = {https://doi.org/10.1016/s1474-4422(26)00318-2}
}

RIS

TY  - JOUR
TI  - HIMALAYA: learning from another negative phase 2 trial in ALS
AU  - Orla Hardiman
PY  - 2026
JO  - The Lancet Neurology
DO  - 10.1016/s1474-4422(26)00318-2
UR  - https://doi.org/10.1016/s1474-4422(26)00318-2
ER  - 

APA

Hardiman, O. (2026). HIMALAYA: learning from another negative phase 2 trial in ALS. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(26)00318-2

Source records